Abstract

Growing evidence indicates that biological heterogeneity of ovarian cancer is associated with a small subpopulation of cancer cells existing within tumor tissue and defined as cancer stem cells (CSCs). This small group of ovarian cells possesses the capacity of self-renewal. Recent data revealed that progression, metastasis and relapse of ovarian cancers are related to the behavior of cancer stem cells. However, how ovarian CSCs maintain their migration properties is still unclear. The clinical relevance of CSCs has been supported by emerging evidence, showing that CSCs are resistant to conventional chemotherapy of ovarian cancer. Identification of biomarkers of ovarian cancer stem cells seems to be important for target therapy. Therapeutic strategies aimed at eliminating CSCs in ovarian cancers might extend disease survival and limit recurrence. This review will describe the current knowledge of ovarian CSCs biology and contribution of these cells to metastasis and chemoresistance of ovarian cancer as well as the possibility to use target therapy of ovarian CSCs.

References

• 1. Baccelli I., Schneeweiss A., Riethdorf S., Stenzinger A., SchillertA, Vogel V., Klein C., Saini M., Bauerle T., Wallwiener M.,Holland-Letz T., Hofner T., Sprick M., Scharpff M., Marme F., SinnHP., Pantel K., Weichert W., Trumpp A.: Identification of a populationof blood circulating tumor cells from breast cancer patientsthat initiates metastasis in a xenograft assay. Nat. Biotechnol.,2013; 31: 539-544
  Google Scholar
• 2. Baccelli I., Trumpp A.: The evolving concept of cancer and metastasisstem cells. J. Cell Biol., 2012; 198: 281-293
  Google Scholar
• 3. Bapat S.A., Mali A.M., Koppikar C.B.,Kurrey N.K.: Stem and progenitor-likecells contribute the aggressive behavior of human epithelialovarian cancer. Cancer Res., 2005; 65: 3025-3029
  Google Scholar
• 4. Bourseau-Guilmain E., Bejaud J., Griveau A., Lautram N., HindréF., Weyland M., Benoit J.P., Garcion E.: Development and characterizationof immuno-nanocarriers targeting the cancer stem cellmarker AC133. Int. J. Pharm., 2011; 423: 93-101
  Google Scholar
• 5. Chen J., Wang J., Zhang Y., Chen D., Yang C., Kai C., Wang X., ShiF., Dou J.: Observation of ovarian cancer stem cell behavior and investigationof potential mechanisms of drug resistance in three-dimensionalcell culture. J. Biosci. Bioeng., 2014; 118: 214-222
  Google Scholar
• 6. Chen K., Huang Y.H., Chen J.L.: Understanding and targetingcancer stem cells: therapeutic implications and challenges. ActaPharmcol. Sin., 2013; 34: 732-740
  Google Scholar
• 7. Cheung K.J., Ewald A.J.: Illuminating breast cancer invasion: diverseroles for cell-cell interactions. Curr. Opin. Cell Biol., 2014; 30:99-111
  Google Scholar
• 8. Foster R., Buckanovich R., Rueda B.: Ovarian cancer stem cells:working towards the root of stemness. Cancer Lett., 2013; 338: 147-157
  Google Scholar
• 9. Gunjal P.M., Schneider G., Ismail A.A. Kakar S.S., Kucia M., RatajczakM.Z.: Evidence for induction of a tumor metastasis-receptivemicroenvironment for ovarian cancer cells in bone marrow andother organs as an unwanted and underestimated side effect ofchemotherapy/radiotherapy. J. Ovarian Res., 2015, 8: 20
  Google Scholar
• 10. Han L., Shi S., Gong T., Zhang Z., Sun X.: Cancer stem cells:therapeutic implications and perspectives in cancer therapy. ActaPharm. Sin., 2013; 3: 65-73
  Google Scholar
• 11. Han X., Du F., Jiang L., Zhu Y., Chen Z., Liu Y., Hong T., Wang T.,Mao Y., Wu X., Bruce I.C., Jin J., Ma X., Hua D.: A2780 human ovariancancer cells with acquired paclitaxel resistance display cancer stemcell properties. Oncol. Lett., 2013; 6: 1295-1298
  Google Scholar
• 12. Hou J.M., Krebs M.G., Lancashire L., Sloane R., Backen A., SwainR.K., Priest L.J., Greystoke A., Zhou C., Morris K., Ward T., BlackhallF.H., Dive C.: Clinical significance and molecular characteristics ofcirculating tumor cells and circulating tumor microemboli in patientswith small-cell lung cancer. J Clin. Oncol., 2012; 30: 525-532
  Google Scholar
• 13. Kasai T., Chen L., Mizutani A., Kudoh T., Murakami H., Fu L., SenoM.: Cancer stem cells converted from pluripotent stem cells and thecancerous niche. J. Stem Cells Regen. Med., 2014; 10: 2-7
  Google Scholar
• 14. Keysar S.B., Jimeno A.: More than markers: Biological significanceof cancer stem cell-defining molecules. Mol. Cancer Ther.,2010; 9: 2450-2457
  Google Scholar
• 15. Landen C.N. Jr, Goodman B., Katre A.A. Steg A.D., Nick A.M.,Stone R.L., Miller L.D., Mejia P.V., Jennings N.B., Gershenson D.M.,Bast R.C. Jr, Coleman R.L., Lopez-Berestein G., Sood A.K.: Targetingaldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol.Cancer Ther., 2010; 9: 3186-3199
  Google Scholar
• 16. Liao W.T., Ye Y.P., Deng Y.J., Bian X.W., Ding Y.Q.: Metastaticcancer stem cells: from the concept to therapeutics. Am. J. StemCells, 2014; 3: 42-62
  Google Scholar
• 17. Long H., Xie R., Xiang T., Zhao Z., Lin S., Lianq Z., Chen Z., ZhuB.: Autocrine CCL5 signaling promotes invasion and migration ofCD133+ ovarian cancer stem-like cells via NF-κB-mediated MMP-9upregulation. Stem Cells., 2012; 30: 2309-2319
  Google Scholar
• 18. Lopez J., Valdez-Morales F.J., Benitez-Bribiesca L.B., Cerbon M.,Carranca A.G.: Normal and cancer stem cells of the human femalereproductive system. Reprod. Biol. Endocrinol., 2013; 11: 53-64
  Google Scholar
• 19. Magee J.A., Piskounova E., Morrison S.J.: Cancer stem cells: impact,heterogeneity, and uncertainty. Cancer Cell., 2012; 21: 283-296
  Google Scholar
• 20. Malecki M., Anderson M., Beauchaine M., Seo S., Tambokan X.,Malecki R.: TRA-1-60+, SSEA-4+, OCT4A+, Nanog+ clones of pluripotentstem cells in the embryonal carcinomas of the ovaries. J. Stem CellRes. Ther., 2012; 2: 130
  Google Scholar
• 21. McAuliffe S.M., Morgan S.L., Wyant G.A., Tran L.T., Muto K.W.,Chen Y.S., Chin K.T., Partridge J.C., Poole B.B., Cheng K.H., Daggett J.Jr, Cullen K., Kantoff E., Hasselbatt K., Berkowitz J., Muto M.G., BerkowitzR.S., Aster J.C., Matulonis U.A., Dinulescu D.M.: Targeting Notch,a key pathway for ovarian cancer stem cells, sensitizes tumors toplatinum therapy. Proc. Natl. Acad. Sci. USA, 2012; 109: 2939-2948
  Google Scholar
• 22. Meng E., Long B., Sullivan P., McClellan S., Finan M.A., Reed E.,Shevde L., Rocconi R.P.: CD44+/CD24- ovarian cancer cells demonstratecancer stem cell properties and correlate to survival. Clin.Exp. Metastasis, 2012; 29: 939-948
  Google Scholar
• 23. Mitsui H., Shibata K., Suzuki S., Umezu T., Mizuno M., KajiyamaH., Kikkawa F.: Functional interaction between peritoneal mesothelialcells and stem cells of ovarian yolk sac tumor (SC-OYST) in peritonealdissemination. Gynecol. Oncol., 2012; 124: 303-310
  Google Scholar
• 24. Pasquier J., Rafii A.: Role of the microenvironment in ovariancancer stem cell maintenance. Biomed Res. Int., 2013; 2013: 630782
  Google Scholar
• 25. Rizzo S., Hersey J.M., Mellor P., Dai W., Santos-Silva A., Liber D.,Luk L., Titley I., Carden C.P., Box G., Hudson D.L., Kaye S.B., BrownR.: Ovarian cancer stem cell-like side populations are enriched followingchemotherapy and overexpress EZH2. Mol. Cancer Ther.,2011;10: 325-335
  Google Scholar
• 26. Sanders M.A., Majumdar A.P.: Colon cancer stem cells: implicationsin carcinogenesis. Front. Biosci., 2014; 16: 1651-1662
  Google Scholar
• 27. Shackleton M.: Normal stem cells and cancer stem cells: similarand different. Sem. Cancer Biol., 2010; 20: 85-92
  Google Scholar
• 28. Shah M.M., Landen C.N.: Ovarian cancer stem cells: Are they realand why are they important? Gynecol. Oncol., 2014; 132: 483-489
  Google Scholar
• 29. Shah V., Taratula O., Garbuzenko G.O., Taratula O.R., Rodriguez–Rodriguez L,. Minko T.: Targeted nanomedicine for suppression ofCD44 and simultaneous cell heath induction in ovarian cancer: anoptimal delivery of siRNA and anticancer drug. Clin. Cancer Res.,2013; 19: 6193-6204
  Google Scholar
• 30. Shank J.J., Yang K., Ghannam J., Cabrera L., Johnston C.J., ReynoldsR.K., Buckanovich R.J.: Metformin targets ovarian cancer stemcells in vitro and in vivo. Gynecol. Oncol., 2012; 127: 390-397
  Google Scholar
• 31. Shiozawa Y., Nie B., Pienta K.J., Morgan T.M., Taichman R.S.:Cancer stem cells and their role in metastasis. Pharmacol. Ther.2013; 138: 285-293
  Google Scholar
• 32. Skubitz A.P., Taras E.P., Boylan K.L., Waldron N.N., Oh S., Panoskaltsis-MortariA., Vallera D.A.: Targeting CD133 in an in vivoovarian cancer model reduces ovarian cancer progression. Gynecol.Oncol., 2013; 130: 579-587
  Google Scholar
• 33. Steg A.D., Bevis K.S., Katre A.A., Ziebarth A., Dobbin Z.C., AlvarezR.D., Zhang K., Conner M., Landen C.N.: Stem cell pathways contributeto clinical chemoresistance in ovarian cancer. Clin. CancerRes., 2012; 18: 869-881
  Google Scholar
• 34. Stower H.: Telomeres: stem cells, cancer and telomerase linkedby WNT. Nat. Rev. Genet., 2012;13: 521
  Google Scholar
• 35. Tanei T., Morimoto K., Shimazu K. Kim S.J., Tanji Y., Taguchi T.,Tamaki Y., Noguchi S.: Association of breast cancer stem cells identifiedby aldehyde dehydrogenase 1 expression with resistance tosequential paclitaxel and epirubicin-based chemotherapy for breastcancers. Clin. Cancer Res., 2009; 15: 4234-4241
  Google Scholar
• 36. Theodoropoulos P.A., Polioudaki H., Agelaki S., Kallergi G., SaridakiZ., Mavrourdis D., Georgoulias V.: Circulating tumor cells witha putative stem cell phenotype in peripheral blood of patients withbreast cancer. Cancer Lett., 2010; 288: 99-106
  Google Scholar
• 37. Tinhofer I., Saki M., Niehr F., Keilholz U., Budach V.: Cancerstem cell characteristics of circulating tumor cells. Int. J. Radiat.Biol., 2014; 90: 622-627
  Google Scholar
• 38. Vinogradov S., Wei X.: Cancer stem cells and drug resistance: thepotential of nanomedicine. Nanomedicine, 2012; 7: 597-615
  Google Scholar
• 39. Wang H., Fan L., Xia X., Rao Y., Ma Q., Yang J., Lu Y., Wang C., MaD., Huang X.: Silencing Wnt2b by siRNA interference inhibits metastasisand enhances chemotherapy sensitivity in ovarian cancer.Int. J. Gynecol. Cancer, 2012; 22: 755-761
  Google Scholar
• 40. Yu Z., Pestell T.G., Lisanti M.P., Pestell R.G.: Cancer stem cells.Int. J. Biochem. Cell Biol., 2012; 44: 2144-2151
  Google Scholar
• 41. Zhang J., Guo X., Chang D.Y., Rosen D.G., Mercado-Uribe I., Liu J.:CD133 expression associated with poor prognosis in ovarian cancer.Mod. Pathol., 2012; 25: 456-464
  Google Scholar
• 42. Zhang S.S., Han Z.P., Jing Y.Y., Tao S.F., Li T.J., Wang H., Wang Y.,Li R., Yang Y., Zhao X., Xu X.D., Yu E.D., Rui Y.C., Liu H.J., Zhang L.,Wei L.X.: CD133+ CXCR4+ colon cancer cells exhibit metastatic potentialand predict poor prognosis of patients. BMC Med., 2012; 10: 85
  Google Scholar
• 43. Zhang Z., Filho M.S., Nor J.E.: The biology of head and neck stemcells. Oral Oncol., 2012; 48: 1-9
  Google Scholar

Full text